| Literature DB >> 35915394 |
Hannah Tuulikki Hohl1, Guenter Froeschl2,3, Michael Hoelscher2,3, Christian Heumann4.
Abstract
BACKGROUND: Numerous scoring tools have been developed for assessing the probability of SARS-COV-2 test positivity, though few being suitable or adapted for outpatient triage of health care workers.Entities:
Keywords: COVID-19; Epidemiology; Germany; Munich; Prediction model; Public health; SARS-COV-2; Triage
Mesh:
Year: 2022 PMID: 35915394 PMCID: PMC9341161 DOI: 10.1186/s12879-022-07627-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Sociodemographic information: frequency and percentage by test result
| Characteristics | Negative (n = 4076) | Positive (n = 121) | Total (n = 4197) | p value | |||
|---|---|---|---|---|---|---|---|
| Age* | 37.9 | 20.0 | 39.9 | 21.0 | 38.0 | 20.0 | 0.090 |
| Gender | |||||||
| Female | 2842 | 69.7% | 89 | 73.6% | 2931 | 69.8% | – |
| Male | 1234 | 30.3% | 32 | 26.4% | 1266 | 30.2% | 0.367 |
| Occupation | |||||||
| Administration | 59 | 1.4% | 1 | 0.8% | 60 | 1.4% | 0.502 |
| Caregiver | 27 | 0.7% | 0 | 0.0% | 27 | 0.6% | NA |
| Cleaner | 30 | 0.7% | 2 | 1.7% | 32 | 0.8% | 0.352 |
| Housekeeping | 29 | 0.7% | 0 | 0.0% | 29 | 0.7% | NA |
| Medical technical assistant | 26 | 0.6% | 0 | 0.0% | 26 | 0.6% | NA |
| No information | 2299 | 56.4% | 77 | 63.6% | 2376 | 56.6% | – |
| Nurse/geriatric nurse/nursing assistant | 722 | 17.7% | 25 | 20.7% | 747 | 17.8% | 0.887 |
| Occupational therapist | 57 | 1.4% | 0 | 0.0% | 57 | 1.4% | NA |
| Other occupation | 371 | 9.1% | 3 | 2.5% | 374 | 8.9% | 0.016 |
| Physician | 234 | 5.7% | 8 | 6.6% | 242 | 5.8% | 0.957 |
| Physiotherapist | 81 | 2.0% | 4 | 3.3% | 85 | 2.0% | 0.460 |
| Researcher/research assistant | 31 | 0.8% | 0 | 0.0% | 31 | 0.7% | NA |
| Speech therapist | 39 | 1.0% | 0 | 0.0% | 39 | 0.9% | NA |
| Student | 52 | 1.3% | 1 | 0.8% | 53 | 1.3% | 0.585 |
| Trainee | 18 | 0.4% | 0 | 0.0% | 18 | 0.4% | NA |
*Age: mean and inter-quartile range. p-value was obtained by univariable logistic regression (NA: p-value calculation not applicable; gender reference “female”, occupation reference “No information”)
Symptoms: frequency and percentage by test result
| Characteristics | Negative (n = 4076) | Positive (n = 121) | Total (n = 4197) | p value | |||
|---|---|---|---|---|---|---|---|
| Symptoms | |||||||
| Asymptomatic | 2805 | 68.8% | 39 | 32.2% | 2844 | 67.8% | – |
| Symptomatic | 1181 | 29.0% | 81 | 66.9% | 1262 | 30.1% | 0.000 |
| No information | 90 | 2.2% | 1 | 0.8% | 91 | 2.2% | NA |
| Days since symptom onset | 5.6 | 6.0 | 4.0 | 3.0 | 5.5 | 6.0 | 0.095 |
| Fever | 201 | 4.9% | 39 | 32.2% | 240 | 5.7% | 0.000 |
| Cough | 572 | 14.0% | 59 | 48.8% | 631 | 15.0% | 0.000 |
| Shortness of breath | 94 | 2.3% | 6 | 5.0% | 100 | 2.4% | 0.067 |
| Sore throat | 690 | 16.9% | 33 | 27.3% | 723 | 17.2% | 0.003 |
| Rhinorrhea | 545 | 13.4% | 52 | 43.0% | 597 | 14.2% | 0.000 |
| Anosmia/Ageusia | 54 | 1.3% | 11 | 9.1% | 65 | 1.5% | 0.000 |
| Sputum production | 27 | 0.7% | 6 | 5.0% | 33 | 0.8% | 0.000 |
| Chest pain | 34 | 0.8% | 6 | 5.0% | 40 | 1.0% | 0.000 |
| Otalgia | 20 | 0.5% | 2 | 1.7% | 22 | 0.5% | 0.076 |
| Wheezing | 11 | 0.3% | 1 | 0.8% | 12 | 0.3% | 0.243 |
| Joint pain | 36 | 0.9% | 13 | 10.7% | 49 | 1.2% | 0.000 |
| Muscle pain | 52 | 1.3% | 15 | 12.4% | 67 | 1.6% | 0.000 |
| Fatigue | 94 | 2.3% | 13 | 10.7% | 107 | 2.5% | 0.000 |
| Headache | 188 | 4.6% | 22 | 18.2% | 210 | 5.0% | 0.000 |
| Confusion | 1 | 0.0% | 0 | 0.0% | 1 | 0.0% | NA |
| Seizure | 1 | 0.0% | 0 | 0.0% | 1 | 0.0% | NA |
| Abdominal pain | 11 | 0.3% | 5 | 4.1% | 16 | 0.4% | 0.000 |
| Nausea/Emesis | 21 | 0.5% | 4 | 3.3% | 25 | 0.6% | 0.000 |
| Diarrhea | 28 | 0.7% | 3 | 2.5% | 31 | 0.7% | 0.023 |
| Conjunctivitis | 5 | 0.1% | 0 | 0.0% | 5 | 0.1% | NA |
| Eczema | 1 | 0.0% | 0 | 0.0% | 1 | 0.0% | NA |
| Lymphadenopathy | 12 | 0.3% | 3 | 2.5% | 15 | 0.4% | 0.001 |
| Bleeding | 2 | 0.0% | 0 | 0.0% | 2 | 0.0% | NA |
*Days since symptom onset: mean and inter-quartile range. p-value was obtained by univariable logistic regression (NA: p-value calculation not applicable). Symptoms were all coded binary (1 = yes, 0 = no), reference is always “no”
Expositions and travel history
| Characteristics | Negative (n = 4076) | Positive (n = 121) | Total (n = 4197) | p value | |||
|---|---|---|---|---|---|---|---|
| Close contact to positive case | |||||||
| Any exposition | 2652 | 65.1% | 104 | 86.0% | 2756 | 65.7% | 0.000 |
| Colleague | 1455 | 35.7% | 47 | 38.8% | 1502 | 35.8% | 0.770 |
| Patient | 923 | 22.6% | 43 | 35.5% | 966 | 23.0% | 0.003 |
| Private | 274 | 6.7% | 13 | 10.7% | 287 | 6.8% | 0.125 |
| Other exposition | 250 | 6.1% | 12 | 9.9% | 262 | 6.2% | 0.131 |
| No exposition | 1194 | 29.3% | 20 | 16.5% | 1214 | 28.9% | 0.001 |
| No information | 370 | 9.1% | 6 | 5.0% | 376 | 9.0% | 0.124 |
| Recent travel abroad | 195 | 4.8% | 7 | 5.8% | 202 | 4.8% | 0.614 |
| 7-day incidence at travel destination (/100,000 inhabitants) (n = 189) | |||||||
| Low (0–35) | 81 | 2.0% | 5 | 4.1% | 86 | 2.0% | 0.623 |
| Medium (35.1–50) | 57 | 1.4% | 2 | 1.7% | 59 | 1.4% | 0.362 |
| High (50.1–150) | 44 | 1.1% | 0 | 0.0% | 44 | 1.0% | 0.471 |
Expositions to SARS-COV-2-positive cases (frequency and percentage by test result), travel history (mean and inter-quartile range). p-value was obtained by univariable logistic regression (incidence reference: non-travellers)
Fig. 17-day incidences per 100,000 inhabitants at the travel destination of tested returnees at the time of testing. Red lines: thresholds for public health measures in Germany
Fig. 2Odds ratios (dark blue) plus 95% confidence interval (light blue) in univariable logistic regression of selected variables and COVID-19 test result with weekly growing dataset. For better readability, upper confidence interval values above 10 have been truncated (orange dots)
Variables selected for logistic regression
| Characteristics | Univariable logistic regression | Multivariable logistic regression model | ||||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio | p value | 95% confidence interval | Odds ratio | p value | 95% confidence interval | |||
| Abdominal pain | 17.56 | 0.000 | 5.99 | 51.51 | 7.38 | 0.070 | 0.85 | 64.36 |
| Any exposition | 3.52 | 0.000 | 1.93 | 6.43 | 3.80 | 0.002 | 1.66 | 8.71 |
| Chest pain | 6.84 | 0.000 | 2.81 | 16.69 | ||||
| Cough | 5.84 | 0.000 | 4.04 | 8.46 | 2.39 | 0.002 | 1.38 | 4.14 |
| Diarrhea | 4.04 | 0.023 | 1.21 | 13.50 | ||||
| Otalgia | 3.77 | 0.076 | 0.87 | 16.37 | ||||
| Sputum production | 8.71 | 0.000 | 3.51 | 21.58 | ||||
| Other exposition | 1.60 | 0.131 | 0.87 | 2.95 | ||||
| Exposition to patient | 1.79 | 0.003 | 1.21 | 2.62 | 1.72 | 0.031 | 1.05 | 2.81 |
| Exposition to private contact | 1.59 | 0.125 | 0.88 | 2.86 | ||||
| Fatigue | 5.76 | 0.000 | 3.11 | 10.67 | ||||
| Fever | 9.25 | 0.000 | 6.14 | 13.92 | 5.78 | 0.000 | 3.11 | 10.74 |
| Headache | 5.24 | 0.000 | 3.20 | 8.59 | ||||
| Joint pain | 15.27 | 0.000 | 7.83 | 29.79 | ||||
| Anosmia/Ageusia | 9.36 | 0.000 | 4.72 | 18.56 | 4.17 | 0.001 | 1.78 | 9.78 |
| Lymphadenopathy | 9.65 | 0.001 | 2.68 | 34.73 | ||||
| Muscle pain | 12.43 | 0.000 | 6.74 | 22.95 | 6.24 | 0.001 | 2.16 | 18.03 |
| Nausea/Emesis | 7.26 | 0.000 | 2.45 | 21.56 | ||||
| Rhinorrhea | 4.88 | 0.000 | 3.36 | 7.08 | ||||
| Shortness of breath | 2.21 | 0.067 | 0.95 | 5.15 | ||||
| Sore throat | 1.85 | 0.003 | 1.23 | 2.78 | ||||
Univariable analysis of clinical signs and epidemiological features associated with COVID-19 with p < 0.2 and multivariable logistic regression of selected variables
Coefficients and weights of variables in derived screening score
| Characteristics | Coefficients | Weights |
|---|---|---|
| Abdominal pain | 2.00 | 4 |
| Anosmia/Ageusia | 1.43 | 3 |
| Any exposition | 1.34 | 3 |
| Cough | 0.87 | 2 |
| Exposition to patient | 0.54 | 1 |
| Fever | 1.75 | 4 |
| Muscle pain | 1.83 | 4 |
Triage scores and assigned risk groups
| Score | Total (n) | Positive (n) | Positive (%) | Sensitivity (%) | Specificity (%) | Assigned risk group |
|---|---|---|---|---|---|---|
| 0 | 846 | 5 | 0.59 | 100 | 0 | Low (n = 939, test positivity = 0.53%) |
| 2 | 93 | 0 | 0.00 | 94 | 26 | |
| 3 | 1257 | 19 | 1.51 | 94 | 28 | Medium (n = 1257, test positivity = 1.51%) |
| 4 | 768 | 17 | 2.21 | 71 | 66 | High (n = 1166, test positivity = 5.06%) |
| 5 | 145 | 3 | 2.07 | 51 | 89 | |
| 6 | 116 | 10 | 8.62 | 47 | 93 | |
| 7 | 34 | 1 | 2.94 | 35 | 97 | |
| 8 | 18 | 2 | 11.11 | 34 | 98 | |
| 9 | 45 | 9 | 20.00 | 31 | 98 | |
| 10 | 17 | 7 | 41.18 | 20 | 99 | |
| 11 | 4 | 1 | 25.00 | 12 | 100 | |
| 12 | 10 | 2 | 20.00 | 11 | 100 | |
| 13 | 6 | 5 | 83.33 | 8 | 100 | |
| 14 | 2 | 1 | 50.00 | 2 | 100 | |
| 15 | 1 | 1 | 100.00 | 1 | 100 |
SARS-COV2 Triage Scores divided into low-, medium-, and high-risk groups
Fig. 3Frequency of patients with positive and negative SARS-COV2 test result by triage score (red/blue bars) and sensitivity and specificity at score cut-offs (green/orange bars). N.B.: For better readability, the frequency of patients is shown in log scale. The red lines indicate the chosen cut-off values for risk group-classification (see below)